All Stories

  1. Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue

    Article • Radiation and Environmental Biophysics, May 2018, Springer Science + Business Media

    Ygal Haupt

  2. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis

    Article • Redox Biology, April 2018, Elsevier

    Ygal Haupt

  3. Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry

    Article • The Prostate, March 2018, Wiley

    Ygal Haupt

  4. Proteotranscriptomic measurements of E6-Associated Protein (E6AP) targets in DU145 prostate cancer cells

    Article • Molecular & Cellular Proteomics, February 2018, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  5. Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice

    Article • Blood Advances, February 2018, American Society of Hematology

    Ygal Haupt

  6. The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort

    Article • International Journal of Radiation Oncology*Biology*Physics, January 2018, Elsevier

    Ygal Haupt

  7. P53 at the start of the 21st century: lessons from elephants

    Article • F1000Research, November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  8. Faculty of 1000 evaluation for Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  9. Faculty of 1000 evaluation for Census and evaluation of p53 target genes.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  10. Faculty of 1000 evaluation for p53 in the DNA-Damage-Repair Process.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  11. Faculty of 1000 evaluation for MicroRNA Control of p53.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  12. Faculty of 1000 evaluation for TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  13. Faculty of 1000 evaluation for Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  14. Faculty of 1000 evaluation for p53 in survival, death and metabolic health: a lifeguard with a licence to kill.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  15. Faculty of 1000 evaluation for The importance of p53 pathway genetics in inherited and somatic cancer genomes.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  16. Faculty of 1000 evaluation for The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  17. Faculty of 1000 evaluation for Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  18. Faculty of 1000 evaluation for Molecular interplay between mutant p53 proteins and autophagy in cancer cells.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  19. Faculty of 1000 evaluation for Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  20. Faculty of 1000 evaluation for The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  21. Faculty of 1000 evaluation for EpiFactors: a comprehensive database of human epigenetic factors and complexes.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  22. Faculty of 1000 evaluation for Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  23. Faculty of 1000 evaluation for p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage.

    Article • November 2017, Faculty of 1000, Ltd.

    Ygal Haupt

  24. New insights on the regulation of INK4/ARF locus expression

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Ygal Haupt

  25. New exciting possibilities for the development of precision medicine therapies to restore the expression of the INK4/ARF locus

    Article • Annals of Research Hospitals, August 2017, AME Publishing Company

    Ygal Haupt

  26. E6AP promotes prostate cancer by reducing p27 expression

    Article • Oncotarget, April 2017, Impact Journals, LLC

    Ygal Haupt

  27. Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

    Article • Nature Communications, March 2017, Springer Science + Business Media

    Ygal Haupt

  28. Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

    Article • Molecular & Cellular Oncology, March 2017, Taylor & Francis

    Ygal Haupt

  29. MDM4 is a rational target for treating breast cancers with mutant p53

    Article • The Journal of Pathology, March 2017, Wiley

    Ygal Haupt

  30. The role of MDM2 and MDM4 in breast cancer development and prevention

    Article • Journal of Molecular Cell Biology, January 2017, Oxford University Press (OUP)

    Dr Andrew Burgess, Ygal Haupt

  31. Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of theINK4/ARFlocus in non–small cell lung cancer

    Article • Science Signaling, January 2017, American Association for the Advancement of Science

    Ygal Haupt

  32. Ubiquitin ligase E6AP mediates nonproteolytic polyubiquitylation of β-catenin independent of the E6 oncoprotein

    Article • Journal of General Virology, December 2016, Society for General Microbiology

    Ygal Haupt

  33. Faculty of 1000 evaluation for The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.

    Article • December 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  34. Faculty of 1000 evaluation for DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

    Article • December 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  35. Faculty of 1000 evaluation for Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

    Article • December 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  36. Faculty of 1000 evaluation for Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

    Article • December 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  37. Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP

    Article • Oncogene, September 2016, Springer Science + Business Media

    Ygal Haupt

  38. Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Ygal Haupt

  39. Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins

    Article • Frontiers in Oncology, July 2016, Frontiers

    Ygal Haupt

  40. The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling

    Article • Cancer Research, May 2016, American Association for Cancer Research (AACR)

    Ygal Haupt

  41. Abstract A72: The E3-ligase E6AP represses breast cancer metastasis through regulation of ECT2-Rho-GTPases signaling

    Article • Molecular Cancer Research, February 2016, American Association for Cancer Research (AACR)

    Ygal Haupt

  42. Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways

    Article • Frontiers in Oncology, January 2016, Frontiers

    Ygal Haupt

  43. Clinical Overview of MDM2/X-Targeted Therapies

    Article • Frontiers in Oncology, January 2016, Frontiers

    Ygal Haupt

  44. Faculty of 1000 evaluation for PDL1 Regulation by p53 via miR-34.

    Article • January 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  45. Faculty of 1000 evaluation for Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.

    Article • January 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  46. Faculty of 1000 evaluation for Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.

    Article • January 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  47. Faculty of 1000 evaluation for Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice.

    Article • January 2016, Faculty of 1000, Ltd.

    Ygal Haupt

  48. Regulation of Mutant p53 Protein Expression

    Article • Frontiers in Oncology, December 2015, Frontiers

    Ygal Haupt

  49. Faculty of 1000 evaluation for Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

    Article • October 2015, Faculty of 1000, Ltd.

    Ygal Haupt

  50. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

    Article • Cancer Research, October 2015, American Association for Cancer Research (AACR)

    Ygal Haupt

  51. Faculty of 1000 evaluation for Ferroptosis as a p53-mediated activity during tumour suppression.

    Article • September 2015, Faculty of 1000, Ltd.

    Ygal Haupt

  52. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

    Article • Gut, July 2015, BMJ

    Ygal Haupt

  53. Targeting Mdmx to treat breast cancers with wild-type p53

    Article • Cell Death and Disease, July 2015, Springer Science + Business Media

    Ygal Haupt

  54. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

    Article • Nature Communications, June 2015, Springer Science + Business Media

    Ygal Haupt

  55. p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress

    Article • Frontiers in Oncology, March 2015, Frontiers

    Ygal Haupt

  56. HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling

    Article • Virology, November 2014, Elsevier

    Ygal Haupt

  57. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death

    Article • Annals of Oncology, September 2014, Oxford University Press (OUP)

    Ygal Haupt

  58. Role of p53 in the progression of gastric cancer

    Article • Oncotarget, September 2014, Impact Journals, LLC

    Ygal Haupt

  59. Faculty of 1000 evaluation for p53 regulates Period2 expression and the circadian clock.

    Article • April 2014, Faculty of 1000, Ltd.

    Ygal Haupt

  60. PML tumour suppression and beyond: Therapeutic implications

    Article • FEBS Letters, February 2014, Wiley

    Ygal Haupt

  61. Co-targeting Deoxyribonucleic Acid–Dependent Protein Kinase and Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Promotes Accelerated Senescence of Irradiated Cancer Cells

    Article • International Journal of Radiation Oncology*Biology*Physics, February 2014, Elsevier

    Ygal Haupt

  62. The p53-Mdm2 Loop: A Critical Juncture of Stress Response

    Article • January 2014, Springer Science + Business Media

    Ygal Haupt

  63. Faculty of 1000 evaluation for A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

    Article • October 2013, Faculty of 1000, Ltd.

    Ygal Haupt

  64. Faculty of 1000 evaluation for Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

    Article • September 2013, Faculty of 1000, Ltd.

    Ygal Haupt

  65. Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain

    Article • Cell Death and Differentiation, June 2013, Springer Science + Business Media

    Ygal Haupt

  66. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner

    Article • Cell Cycle, June 2013, Taylor & Francis

    Ygal Haupt

  67. Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells

    Article • ACS Chemical Biology, May 2013, American Chemical Society (ACS)

    Ygal Haupt

  68. c-Abl Phosphorylates E6AP and Regulates Its E3 Ubiquitin Ligase Activity

    Article • Biochemistry, April 2013, American Chemical Society (ACS)

    Ygal Haupt

  69. Faculty of 1000 evaluation for Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

    Article • April 2013, Faculty of 1000, Ltd.

    Ygal Haupt

  70. Stimulating p53 down-under: a report from the 1st Australian p53 Workshop

    Article • Cell Death and Differentiation, February 2013, Springer Science + Business Media

    Ygal Haupt

  71. Faculty of 1000 evaluation for Dietary downregulation of mutant p53 levels via glucose restriction: Mechanisms and implications for tumor therapy.

    Article • January 2013, Faculty of 1000, Ltd.

    Ygal Haupt

  72. New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers

    Article • Frontiers in Oncology, January 2013, Frontiers

    Ygal Haupt

  73. Faculty of 1000 evaluation for p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

    Article • November 2012, Faculty of 1000, Ltd.

    Ygal Haupt

  74. Restoring PML tumor suppression to combat cancer

    Article • Cell Cycle, October 2012, Taylor & Francis

    Ygal Haupt

  75. The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress

    Article • Oncogene, September 2012, Springer Science + Business Media

    Ygal Haupt

  76. MDM4 is a key therapeutic target in cutaneous melanoma

    Article • Nature Medicine, July 2012, Springer Science + Business Media

    Ygal Haupt

  77. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis

    Article • Blood, June 2012, American Society of Hematology

    Ygal Haupt

  78. Faculty of 1000 evaluation for Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.

    Article • May 2012, Faculty of 1000, Ltd.

    Ygal Haupt

  79. Faculty of 1000 evaluation for Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

    Article • March 2012, Faculty of 1000, Ltd.

    Ygal Haupt

  80. Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption

    Article • Cell Cycle, January 2012, Taylor & Francis

    Ygal Haupt

  81. Faculty of 1000 evaluation for Melatonin triggers p53(Ser) phosphorylation and prevents DNA damage accumulation.

    Article • December 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  82. Faculty of 1000 evaluation for Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

    Article • December 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  83. Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer

    Article • Journal of Drug Targeting, November 2011, Taylor & Francis

    Ygal Haupt

  84. Faculty of 1000 evaluation for Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice.

    Article • October 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  85. E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts

    Article • Oncogene, September 2011, Springer Science + Business Media

    Ygal Haupt

  86. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy

    Article • Oncogene, September 2011, Springer Science + Business Media

    Ygal Haupt

  87. Faculty of 1000 evaluation for A continuum model for tumour suppression.

    Article • August 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  88. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer:

    Article • Biochemical Journal, August 2011, Portland Press Ltd.

    Ygal Haupt

  89. Faculty of 1000 evaluation for Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.

    Article • June 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  90. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer

    Article • Biochemical Journal, June 2011, Portland Press Ltd.

    Ygal Haupt

  91. Faculty of 1000 evaluation for Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

    Article • April 2011, Faculty of 1000, Ltd.

    Ygal Haupt

  92. Faculty of 1000 evaluation for A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

    Article • December 2010, Faculty of 1000, Ltd.

    Ygal Haupt

  93. MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation

    Article • Journal of Cell Science, June 2010, The Company of Biologists

    Ygal Haupt

  94. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner

    Article • Virology, January 2010, Elsevier

    Ygal Haupt

  95. The p53-Mdm2 Loop: A Critical Juncture of Stress Response

    Article • January 2010, Springer Science + Business Media

    Ygal Haupt

  96. P53 and Cell Death

    Article • December 2009, Wiley

    Ygal Haupt

  97. Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

    Article • Cancer Research, June 2009, American Association for Cancer Research (AACR)

    Ygal Haupt

  98. E6AP promotes the degradation of the PML tumor suppressor

    Article • Cell Death and Differentiation, March 2009, Springer Science + Business Media

    Ygal Haupt

  99. Tumour suppression by p53: the importance of apoptosis and cellular senescence

    Article • The Journal of Pathology, January 2009, Wiley

    Ygal Haupt

  100. T cell survival and function requires the c-Abl tyrosine kinase

    Article • Cell Cycle, December 2008, Taylor & Francis

    Ygal Haupt

  101. c-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53

    Article • Journal of Biological Chemistry, December 2008, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  102. Chromatin Immunoprecipitation-on-Chip Reveals Stress-Dependent p53 Occupancy in Primary Normal Cells but Not in Established Cell Lines

    Article • Cancer Research, December 2008, American Association for Cancer Research (AACR)

    Ygal Haupt

  103. p53 controls hPar1 function and expression

    Article • Oncogene, September 2008, Springer Science + Business Media

    Ygal Haupt

  104. PML enhances the regulation of p53 by CK1 in response to DNA damage

    Article • Oncogene, February 2008, Springer Science + Business Media

    Ygal Haupt

  105. Importance of p53 for cancer onset and therapy

    Article • Anti-Cancer Drugs, August 2006, Wolters Kluwer Health

    Ygal Haupt

  106. Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species

    Article • Anti-Cancer Drugs, July 2006, Wolters Kluwer Health

    Ygal Haupt

  107. Clues from worms: a Slug at Puma promotes the survival of blood progenitors

    Article • Cell Death and Differentiation, March 2006, Springer Science + Business Media

    Ygal Haupt

  108. Tumor suppressor p53 regulates heparanase gene expression

    Article • Oncogene, February 2006, Springer Science + Business Media

    Ygal Haupt

  109. Mutations in Proline 82 of p53 Impair Its Activation by Pin1 and Chk2 in Response to DNA Damage

    Article • Molecular and Cellular Biology, July 2005, ASM Journals

    Ygal Haupt

  110. C-Abl as a modulator of p53

    Article • Biochemical and Biophysical Research Communications, June 2005, Elsevier

    Ygal Haupt

  111. Mdm2 in growth signaling and cancer

    Article • Growth Factors, January 2005, Taylor & Francis

    Ygal Haupt

  112. Treatment of Chronic Myeloid Leukemia Cells with Imatinib (STI571) Impairs p53 Accumulation in Response to DNA Damage

    Article • Cell Cycle, September 2004, Taylor & Francis

    Ygal Haupt

  113. Manipulation of the tumor suppressor p53 for potentiating cancer therapy

    Article • Seminars in Cancer Biology, August 2004, Elsevier

    Ygal Haupt

  114. Improving Cancer Therapy through p53 Management

    Article • Cell Cycle, July 2004, Taylor & Francis

    Ygal Haupt

  115. Introduction: p53 Regulation—A Family Affair

    Article • Cell Cycle, July 2004, Taylor & Francis

    Ygal Haupt

  116. Apoptosis - the p53 network

    Article • Journal of Cell Science, October 2003, The Company of Biologists

    Ygal Haupt

  117. The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation

    Article • Journal of Biological Chemistry, June 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  118. Certainly No ARFterthought: Oncogenic Cooperation in ARF Induction —A Key Step in Tumor Suppression

    Article • Cell Cycle, March 2003, Taylor & Francis

    Ygal Haupt

  119. P53 licensed to kill? Operating the assassin

    Article • Journal of Cellular Biochemistry, December 2002, Wiley

    Ygal Haupt

  120. Deconstruction of p53 functions and regulation

    Article • Oncogene, November 2002, Springer Science + Business Media

    Ygal Haupt

  121. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation

    Article • The EMBO Journal, July 2002, Wiley

    Ygal Haupt

  122. p53: An Internal Investigation

    Article • Cell Cycle, March 2002, Taylor & Francis

    Ygal Haupt

  123. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33ING1 in T.Tn human esophageal carcinoma cells

    Article • Oncogene, February 2002, Springer Science + Business Media

    Ygal Haupt

  124. c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination

    Article • Molecular and Cellular Biology, September 2001, ASM Journals

    Ygal Haupt

  125. Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53

    Article • Oncogene, January 2001, Springer Science + Business Media

    Ygal Haupt

  126. A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2

    Article • Journal of Biological Chemistry, October 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  127. c-Jun and p53 Activity Is Modulated by SUMO-1 Modification

    Article • Journal of Biological Chemistry, April 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  128. p53 and thymic ‘death by neglect’: thymic epithelial cell-induced apoptosis of CD4+8+ thymocytes is p53-independent

    Article • Cell Death and Differentiation, March 2000, Springer Science + Business Media

    Ygal Haupt

  129. The cellular response to p53: the decision between life and death

    Article • Oncogene, November 1999, Springer Science + Business Media

    Ygal Haupt

  130. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity

    Article • Oncogene, May 1999, Springer Science + Business Media

    Ygal Haupt

  131. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2

    Article • The EMBO Journal, April 1999, Wiley

    Ygal Haupt

  132. c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53

    Article • Journal of Biological Chemistry, March 1999, American Society for Biochemistry & Molecular Biology (ASBMB)

    Ygal Haupt

  133. The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb

    Article • Molecular and Cellular Biology, July 1998, ASM Journals

    Ygal Haupt

  134. Apoptosis by p53: mechanisms, regulation, and clinical implications

    Article • Springer Seminars in Immunopathology, January 1998, Springer Science + Business Media

    Ygal Haupt

  135. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis

    Article • The EMBO Journal, July 1997, Wiley

    Ygal Haupt

  136. Mdm2 promotes the rapid degradation of p53

    Article • Nature, May 1997, Springer Science + Business Media

    Ygal Haupt

  137. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.

    Article • Molecular and Cellular Biology, September 1996, ASM Journals

    Ygal Haupt

  138. P53-Mediated Apoptosis

    Article • January 1996, Springer Science + Business Media

    Ygal Haupt

  139. Induction of apoptosis in HeLa cells by trans-activation-deficient p53.

    Article • Genes & Development, September 1995, Cold Spring Harbor Laboratory Press

    Ygal Haupt

  140. A functional p53-responsive intronic promoter is contained within the humanmdm2gene

    Article • Nucleic Acids Research, January 1995, Oxford University Press (OUP)

    Ygal Haupt

  141. Moloney virus induction of T-cell lymphomas in a plasmacytomagenic strain of Eμ-V-ABL transgenic mice

    Article • International Journal of Cancer, October 1993, Wiley

    Ygal Haupt

  142. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice

    Article • Cell, May 1991, Elsevier

    Ygal Haupt

  143. Flow Cytometric Analysis of p53-Induced Apoptosis

    Article • Springer Science + Business Media

    Ygal Haupt